The proportion of responders to the isogenic strain 44/76 FetAoffPorAonwere 39% and 32% in the 25g and 50g dose groups respectively at baseline, increasing to 91% and 96% after 3 doses (Fig.3C). with SBA titres 1:4 (the putative protective titre) was 98% for the wild-type strain, and 77% for the strain 44/76 FetAonPorAoffcompared to 51% in the strain 44/76 FetAoffPorAoff, demonstrating that vaccination with MenPF-1 simultaneously induced FetA and PorA bactericidal antibodies. == Conclusion == This study provides a proof-of-concept for generating bactericidal antibodies against FetA after OMV vaccination in humans. Prevalence-based choice of PorA and FetA types can be used to formulate a vaccine for broad protection against MenB disease. Keywords:Neisseria meningitidis, Vaccine, Outer membrane vesicles, FetA, Molecular epidemiology == Highlights == MenB OMV vaccines’ efficacy is strain-restricted by the variable antigen PorA. FetA is usually another variable antigen, but has iron-dependent expression. The combination of only a few PorA and FetA can induce broad-protection. A mutated OMV was created made up of one PorA and one FetA. FetA induces bactericidal antibody response in addition to the PorA response in a Phase I trial. == Introduction == Capsular group BNeisseria meningitidis(MenB) is the predominant cause Dolutegravir Sodium of invasive meningococcal disease (IMD) in most European countries.1In the USA, groups B, C and Y cause IMD in similar proportions. 2Invasive MenB disease has declined recently, but still caused 595/769 (77%) of all cases of IMD in the UK in 2012/13,3with an incidence of 1 1.8/100,000 per year in the period 20062012.4The rapid onset of severe disease, potentially resulting in death or significant disability, maintains MenB as a priority for Dolutegravir Sodium vaccine development. Successes with meningococcal A, C,Y and W polysaccharideprotein conjugate vaccines have not been reproduced with MenB, perhaps due to antigenic similarity of group B capsule sialic acid and human foetal neuronal cells, which is also a security concern.5,6This has led to the development of formulations based on outer membrane vesicles (OMVs) containing PorA and other outer membrane proteins.7OMV vaccines have been shown to be safe, to induce protective serosubtype (PorA)-specific immune responses, and have been used to successfully control clonal outbreaks of MenB disease.814However, these vaccines offer limited protection against different serosubtypes (PorA types) of MenB. The vaccine 4CMenB, recently licensed in Australia, Europe, Canada and the US, includes an OMV component in addition to recombinant proteins15to induce protection against one PorA type.16 The PorA type-specificity of OMV vaccines occurs because most bactericidal antibodies are directed against specific surface-exposed epitopes on PorA, which are highly variable. This means that multiple PorA types are required to cover different strains.1719FetA is an additional vaccine candidate, being a variable subcapsular antigen that has been shown to induce bactericidal antibodies in animal models2023and to a certain extent during clinical trials, where immune responses against FetA can be Mouse monoclonal to CD95(FITC) detected.21,2426As a consequence of iron-dependent regulation of its expression during culture,27the amount of FetA is variable in OMV vaccines, ranging from 0 to 9% of the total protein content of MenBVac and MeNZB, used in Norway and New Zealand, respectively.28,29FetA is a TonB-coupled transporter, but its physiologically relevant substrate is unclear: FetA fromN. meningitidishas been shown to bind ferric ironin vitro.30Studies on FetA fromNeisseria gonorrhoeaehave shown that it can transport a range of ferric catecholate-type siderophores.31 Hyper-invasive lineages, those meningococcal genotypes causing the majority of invasive disease, exhibit stable, non-overlapping structures of their variable antigens, which limits antigenic diversity.32Analysis of the molecular epidemiology of 4057 clinical IMD isolates obtained between Dolutegravir Sodium 2000 and 2002, across 18 European countries, revealed that 5/31 clonal complexes accounted for 77% of isolates.33,34Eight out of 273 PorA types accounted for 60% of isolates, and 6/99 FetA types accounted for 67% of isolates (Unpublished results). Therefore, although these antigens are diverse, only a few combinations of subtypes are responsible for the majority of IMD and choice of a limited quantity of PorA and FetA protein combinations based on surveillance data has potential in designing a vaccine that harnesses the immunogenicity of these proteins. As FetA immunogenicity is usually less certain than PorA, which is usually immunodominant, we aimed to demonstrate that constitutive expression of FetA in.
